The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.

Saved in:
Bibliographic Details
Title: The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Authors: Sudhakar N; Mirati Therapeutics, Inc., San Diego, California., Yan L; Mirati Therapeutics, Inc., San Diego, California., Qiryaqos F; Mirati Therapeutics, Inc., San Diego, California., Engstrom LD; Mirati Therapeutics, Inc., San Diego, California., Laguer J; Mirati Therapeutics, Inc., San Diego, California., Calinisan A; Mirati Therapeutics, Inc., San Diego, California., Hebbert A; Mirati Therapeutics, Inc., San Diego, California., Waters L; Mirati Therapeutics, Inc., San Diego, California., Moya K; Mirati Therapeutics, Inc., San Diego, California., Bowcut V; Mirati Therapeutics, Inc., San Diego, California., Vegar L; Mirati Therapeutics, Inc., San Diego, California., Ketcham JM; Mirati Therapeutics, Inc., San Diego, California., Ivetac A; Mirati Therapeutics, Inc., San Diego, California., Smith CR; Mirati Therapeutics, Inc., San Diego, California., Lawson JD; Mirati Therapeutics, Inc., San Diego, California., Rahbaek L; Mirati Therapeutics, Inc., San Diego, California., Clarine J; Mirati Therapeutics, Inc., San Diego, California., Nguyen N; Mirati Therapeutics, Inc., San Diego, California., Saechao B; Mirati Therapeutics, Inc., San Diego, California., Parker C; Mirati Therapeutics, Inc., San Diego, California., Elliott AJ; Mirati Therapeutics, Inc., San Diego, California., Vanderpool D; Mirati Therapeutics, Inc., San Diego, California., He L; Monoceros Biosciences LLC, San Diego, California., Hover LD; Monoceros Biosciences LLC, San Diego, California., Fernandez-Banet J; Monoceros Biosciences LLC, San Diego, California., Coma S; Verastem Oncology, Needham, Massachusetts., Pachter JA; Verastem Oncology, Needham, Massachusetts., Hallin J; Mirati Therapeutics, Inc., San Diego, California., Marx MA; Mirati Therapeutics, Inc., San Diego, California., Briere DM; Mirati Therapeutics, Inc., San Diego, California., Christensen JG; Mirati Therapeutics, Inc., San Diego, California., Olson P; Mirati Therapeutics, Inc., San Diego, California., Haling J; Mirati Therapeutics, Inc., San Diego, California., Khare S; Mirati Therapeutics, Inc., San Diego, California.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Oct 01; Vol. 23 (10), pp. 1418-1430.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-8514
DOI:10.1158/1535-7163.MCT-23-0870